Difesa Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Difesa Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,000	Closed	-$199K	–	22
2023 Q2	$199K	Buy	11,000 +800	+8%	+$18.9K	0.52%	23
2023 Q1	$271K	Hold	10,200	–	–	0.18%	67
2022 Q4	$197K	Hold	10,200	–	–	0.15%	85
2022 Q3	$213K	Hold	10,200	–	–	0.11%	95
2022 Q2	$82K	Hold	10,200	–	–	0.05%	120
2022 Q1	$72K	Hold	10,200	–	–	0.04%	141
2021 Q4	$138K	Buy	+10,200	New	+$162K	0.09%	122

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Difesa Capital Management's PLRX Position: Q3 2023 in Review

Difesa Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 11,000 shares — an estimated $199K sold.

Difesa Capital Management first reported a position in PLRX in Q4 2021 and held it in 7 quarters. The position peaked at $271K in Q1 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

Difesa Capital Management reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
Difesa Capital Management sold 11,000 Pliant Therapeutics shares in Q3 2023, an estimated $199K.
Difesa Capital Management first reported a position in Pliant Therapeutics in Q4 2021 and held it in 7 quarters.
Difesa Capital Management's Pliant Therapeutics position peaked at $271K in Q1 2023.
136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Difesa Capital Management's 13F filing for Q3 2023.